UPSA Dafalgan Codéine

Dafalgan Codéine is a specialized analgesic medication combining paracetamol and codeine, designed to treat moderate to intense pain. It is an extension of the widely recognized Dafalgan brand, which has been a staple of French pharmacy cabinets for decades.

The product is manufactured in France, specifically at the UPSA facilities in Agen. This production site is one of the largest pharmaceutical manufacturing hubs in Europe, reflecting the brand's long-standing commitment to French industrial expertise.

Historically, the brand belonged to Bristol Myers Squibb (BMS). However, in 2019, the UPSA group was acquired by the Japanese pharmaceutical giant Taisho Pharmaceutical. This acquisition marked a significant shift in ownership, positioning UPSA as a key subsidiary of a global leader in over-the-counter and prescription healthcare products based in Tokyo.